Grid Therapeutics, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grid Therapeutics, LLC
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic
Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.
Venture Funding Deals: Spin-Offs Gain Their Own Footing
Pfizer-backed SpringWorks, ProQR spin-out Amylon and Landos, the first firm out of accelerator Xontogeny, gain their own financing. Other venture rounds support Autolus, Grid Therapeutics, Excision and more.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.